Trending Stock News

Massachusetts Financial Services Company Trimmed Pnc Finl Svcs Group (PNC) Holding By $13.87 Million; Profile of 6 Analysts Covering Achillion Pharmaceuticals, Inc. (ACHN)

The PNC Financial Services Group, Inc. (NYSE:PNC) Logo

Massachusetts Financial Services Company decreased Pnc Finl Svcs Group Inc (PNC) stake by 0.9% reported in 2018Q1 SEC filing. Massachusetts Financial Services Company sold 91,840 shares as Pnc Finl Svcs Group Inc (PNC)’s stock declined 8.45%. The Massachusetts Financial Services Company holds 10.08 million shares with $1.52 billion value, down from 10.17 million last quarter. Pnc Finl Svcs Group Inc now has $66.38 billion valuation. The stock decreased 0.54% or $0.77 during the last trading session, reaching $141.38. About 1.87M shares traded. The PNC Financial Services Group, Inc. (NYSE:PNC) has risen 21.98% since June 20, 2017 and is uptrending. It has outperformed by 9.41% the S&P500.

Among 12 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Achillion Pharma had 28 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Buy” rating given on Thursday, August 13 by Maxim Group. Maxim Group maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Wednesday, August 9 with “Buy” rating. The firm has “Buy” rating by UBS given on Tuesday, September 8. The firm has “Outperform” rating by Leerink Swann given on Thursday, May 18. The company was initiated on Thursday, September 15 by FBR Capital. As per Friday, August 11, the company rating was maintained by Leerink Swann. The rating was upgraded by Robert W. Baird to “Outperform” on Friday, February 26. The rating was downgraded by Robert W. Baird on Thursday, August 10 to “Neutral”. FBR Capital initiated the shares of ACHN in report on Wednesday, February 7 with “Hold” rating. As per Wednesday, August 9, the company rating was maintained by Chardan Capital Markets. See Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) latest ratings:

21/05/2018 Broker: Barclays Capital Rating: Hold New Target: $5.0000 Upgrade
23/02/2018 Broker: FBR Capital Rating: Hold Maintain
07/02/2018 Broker: FBR Capital Rating: Hold New Target: $3.5 Initiate
08/02/2018 Broker: B. Riley & Co Rating: Neutral New Target: $3.5 Initiates Coverage On

The stock increased 6.27% or $0.18 during the last trading session, reaching $3.05. About 919,101 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 13.49% since June 20, 2017 and is downtrending. It has underperformed by 26.06% the S&P500. Some Historical ACHN News: ; 15/05/2018 – Sarissa Adds Shire, Cuts Achillion: 13F; 14/05/2018 – Morgan Stanley Capital Services Exits Position in Achillion; 09/05/2018 – Achillion Short-Interest Ratio Rises 53% to 12 Days; 07/05/2018 – Achillion at Deutsche Bank Health Care Conference Tomorrow; 02/05/2018 – ACHILLION 1Q LOSS/SHR 15C, EST. LOSS/SHR 14C; 02/05/2018 – Achillion Pharmaceuticals: Milind S. Deshpande Stepping Down as CEO, Will Continue as Consultant to Compan; 02/05/2018 – ACHILLION 1Q CASH & CASH EQUIVALENTS $308.4M; 15/05/2018 – Armistice Capital Buys New 3.1% Position in Achillion; 02/05/2018 – Achillion Pharmaceuticals Appoints Joseph Truitt CEO; 14/05/2018 – Great Point Partners Buys New 2.7% Position in Achillion

Another recent and important Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news was published by Globenewswire.com which published an article titled: “Achillion to Present at the 2018 JMP Securities Life Sciences Conference” on June 14, 2018.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $421.94 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Investors sentiment decreased to 0.95 in 2018 Q1. Its down 1.13, from 2.08 in 2017Q4. It dived, as 26 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 17 funds opened positions while 35 raised stakes. 107.48 million shares or 2.61% less from 110.36 million shares in 2017Q4 were reported. 41,013 were reported by Metropolitan Life Ins Company Ny. Balyasny Asset Management Lc reported 45,634 shares. Architects owns 1,200 shares. Schwab Charles Invest Mgmt Inc invested in 0% or 700,848 shares. Renaissance Tech Limited Company accumulated 875,899 shares or 0% of the stock. State Board Of Administration Of Florida Retirement reported 0% stake. Minnesota-based Ameriprise Fincl has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Sarissa Mgmt Ltd Partnership has 0.43% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 500,000 shares. Price T Rowe Associate Md reported 0% stake. Moreover, Baker Bros Advisors Limited Partnership has 0.09% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). State Street Corporation has 5.92 million shares. South Dakota Inv Council invested 0.07% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Dafna Management Limited Liability invested in 1.57% or 868,272 shares. Dimensional Fund Limited Partnership holds 0.01% or 6.04 million shares in its portfolio.

Since January 17, 2018, it had 0 insider buys, and 1 insider sale for $1.24 million activity. 8,011 shares were sold by HANNON MICHAEL J, worth $1.24 million.

Among 34 analysts covering PNC Financial Services (NYSE:PNC), 13 have Buy rating, 1 Sell and 20 Hold. Therefore 38% are positive. PNC Financial Services had 109 analyst reports since August 6, 2015 according to SRatingsIntel. The company was upgraded on Monday, July 17 by Rafferty. The firm earned “Buy” rating on Tuesday, July 25 by Deutsche Bank. The stock of The PNC Financial Services Group, Inc. (NYSE:PNC) earned “Buy” rating by Piper Jaffray on Monday, January 15. The firm has “Buy” rating by Robert W. Baird given on Tuesday, October 31. The rating was upgraded by KBW to “Market Perform” on Wednesday, September 2. Robert W. Baird maintained The PNC Financial Services Group, Inc. (NYSE:PNC) rating on Monday, August 28. Robert W. Baird has “Buy” rating and $135.0 target. The stock has “Buy” rating by RBC Capital Markets on Friday, January 12. The stock of The PNC Financial Services Group, Inc. (NYSE:PNC) earned “Hold” rating by Jefferies on Monday, September 26. Jefferies maintained the shares of PNC in report on Sunday, April 15 with “Hold” rating. The stock has “Hold” rating by Susquehanna on Monday, January 15.

Investors sentiment decreased to 0.72 in Q1 2018. Its down 0.32, from 1.04 in 2017Q4. It fall, as 54 investors sold PNC shares while 421 reduced holdings. 91 funds opened positions while 253 raised stakes. 373.26 million shares or 0.84% less from 376.44 million shares in 2017Q4 were reported. Mason Street Ltd Limited Liability Company holds 65,691 shares or 0.23% of its portfolio. 6.17 million are held by Jennison Assocs Ltd Liability Corporation. First Republic Investment Management invested in 0.54% or 450,145 shares. Gulf Fincl Bank (Uk) has invested 0.3% in The PNC Financial Services Group, Inc. (NYSE:PNC). Hm Payson Comm holds 0.02% of its portfolio in The PNC Financial Services Group, Inc. (NYSE:PNC) for 2,973 shares. Proshare Limited Liability Corporation holds 0.15% or 150,769 shares in its portfolio. Linscomb Williams Incorporated stated it has 0.03% of its portfolio in The PNC Financial Services Group, Inc. (NYSE:PNC). Conning Inc accumulated 23,415 shares or 0.11% of the stock. Hanseatic Management Services reported 0.07% in The PNC Financial Services Group, Inc. (NYSE:PNC). Balasa Dinverno & Foltz Ltd Llc, a Illinois-based fund reported 1,841 shares. Hightower Ltd Limited Liability Company holds 536,323 shares. Mcf Advsr Ltd Llc invested in 1,675 shares or 0.05% of the stock. Virginia Retirement Systems Et Al holds 0.17% in The PNC Financial Services Group, Inc. (NYSE:PNC) or 91,000 shares. Tower Bridge Advisors has invested 0% in The PNC Financial Services Group, Inc. (NYSE:PNC). 134,709 are owned by Fjarde Ap.

Massachusetts Financial Services Company increased Pvh Corp (NYSE:PVH) stake by 6,285 shares to 440,092 valued at $66.64 million in 2018Q1. It also upped Kohls Corp (NYSE:KSS) stake by 546,801 shares and now owns 599,604 shares. Express Inc (NYSE:EXPR) was raised too.

The PNC Financial Services Group, Inc. (NYSE:PNC) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *